Additional file 1: of Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure S1. Recurrence of IMC after ICI resumption. Figure S2. Kaplan-Meier curve showing overall survival duration of patients who received vedolizumab only compared with that of patients who received infliximab with or without vedolizumab. Figure S3. Kaplan-Meier curve showing overall survival duration of patients who developed IMC after more than three infusions of ICI compared with those who developed IMC after three or fewer infusions. (DOCX 61 kb